UNASSIGNED: 52 Background: There is an increasing incidence of @entity788 over time, a @entity5 with a 5-year survival rate of only 7.2%.For @entity1 with poor prognosis @entity5 , hospice is an important resource, but it is often not utilized or underutilized. Factors influencing hospice use are difficult to determine. We sought to evaluate the impact of @entity788 treatment on hospice utilization. METHODS: National Surveillance Epidemiology and End Results (SEER)-Medicare data was utilized to identify all incident cases of @entity788 @entity1 who died (2005-09, with follow up to 2011). @entity1 were stratified by primary treatment strategy: surgery, chemotherapy, or no treatment. Hospice utilization in the last 6 months of life, including average and median days enrolled in hospice and average time from diagnosis to hospice was evaluated. RESULTS: 17,031 @entity1 were identified, with 68.5% enrolling in hospice in the last 6 months of life. @entity1 undergoing surgery were less likely to enroll in hospice compared to @entity1 not undergoing surgery (58.7% vs 69.4%, p < 0.0001). Interestingly, surgical @entity1 spent on average 31.2 days in hospice (median 15.0 days) which was comparable to the non-surgical cohort (average 32.7 days, median 16.0 days; p = 0.32). @entity1 who received any chemotherapy spent an average of 29.2 days in hospice (median 15 days) compared to those who did not undergo chemotherapy, who spent an average of 34.5 days in hospice (median 16 days); p < 0.0001. While total hospice enrollment was equivalent between the chemotherapy and no chemotherapy cohorts (67.5% vs 69.1%), the time spent in hospice was significantly different (p < 0.0001). @entity1 not receiving any @entity5 -directed treatment enrolled in hospice at an average of 78.6 days (median 32 days) from diagnosis. CONCLUSIONS: @entity788 @entity1 undergoing surgery enrolled in hospice to a much lesser extent than @entity1 who did not have surgery. @entity1 not receiving @entity5 -directed treatment spend a relatively short time in hospice. Overall, hospice appears to be underutilized, and the majority of @entity1 with this poor prognosis @entity5 are not realizing the full benefits of hospice.

Impact of XXXX treatment on hospice utilization.

@entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['Pancreatic cancer', 'pancreatic cancer']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic cancer']
